Irritable bowel syndrome (IBS) is a common functional bowel disorder with estimated regional prevalence rates ranging from 5.8% to 17.5%. 1 The complex pathophysiology of IBS remains incompletely understood, but may involve both central and peripheral mechanisms including alterations in the brain-gut axis, gastrointestinal (GI) motility, intestinal permeability, local immune responses, low-grade inflammation, visceral hypersensitivity, and intestinal microbiota. 
aforementioned central and peripheral mechanisms, and through their production of microbial metabolic products. 4, 5 Composition of the human intestinal microbiota is shaped by various host-specific and environmental factors. 5, 6 Thus, antibiotic and probiotic therapies have been considered as potential treatments to target the intestinal dysbiosis or microbial imbalance that may exist in IBS.
Probiotics are live microorganisms that when consumed by the host in adequate amounts, may confer beneficial health effects. 7 Probiotics have long been used in the treatment of many GI symptoms. They are easily available and have been extensively studied.
Unfortunately, most studies have been of suboptimal quality with significant heterogeneity in study endpoints and methodological rigor.
A prior systematic review of probiotics in IBS reported evidence for efficacy on persistent symptoms, global IBS and abdominal pain scores. However, evidence for benefit with individual strains or specific combinations was not shown. 8 Preclinical studies have demonstrated strain-specific effects of probiotics, which should be taken into consideration when prescribing probiotics in the clinical setting. 9 Several strains and combinations of strains are currently available for IBS therapy, with Lactobacillus sp. and Bifidobacterium sp. 8, 9 most frequently studied. A specific probiotic combination, VSL#3, is a patented 
| ME THODS

| Search strategy and study selection
The study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses. 16 A search of the medical literature was conducted in May 2017 using MEDLINE (OvidSP and PubMed interfaces), EMBASE,
Web of Science, and Scopus by an experienced medical librarian (JH)
with input from study investigators. Studies were identified using a search strategy that included relevant keywords and Medical Subject Headings (MESH) to retrieve randomized controlled trials of VSL#3
for patients with IBS. A focus on treatment outcome and impact on abdominal pain and bowel function was also included. The search strategy contained a combination of MESH terms and keywords that included terms related to "Irritable Bowel Syndrome"; "Probiotics"
OR "VSL #3.mp"; "Treatment outcome" OR "Abdominal Pain".) The search strategy is shown in Appendix 1. Randomized trials (RCTs) comparing VSL#3 with placebo among patients with IBS were eligible for inclusion. No date limitations or language restrictions were applied. All trials were eligible for inclusion regardless of publicationtype. First period data from cross-over studies were eligible for inclusion. Abstracts and titles identified from the search strategy were assessed by two independent investigators (AS and MC) for eligibility. All potentially relevant studies were subsequently obtained for a
full-text review. Bibliographies of eligible studies, available reviews and clinicaltrials.gov were reviewed. Conference abstracts and clinicaltrials.gov were manually searched to identify potentially eligible studies. Conflicting decisions were resolved by discussion.
| Eligibility criteria
Eligible for inclusion were randomized placebo-controlled trials examining effects of VSL#3 on outcomes of abdominal pain and stool consistency in patients with IBS. Any definition of IBS, including physician diagnosis or symptom-based diagnostic criteria, was satisfactory for inclusion. Studies investigating patients with other organic GI conditions including inflammatory bowel disease, microscopic colitis, celiac disease or infectious colitis were excluded. No minimum duration of therapy was applied. Studies had to report data on at least one of the primary outcomes: abdominal pain or stool consistency.
| Study outcomes
The primary outcomes were effects of VSL#3 on mean improvements in abdominal pain and stool consistency. Secondary outcomes were effects of treatment on overall response, abdominal bloating, and QOL. We also assessed the frequency and types of adverse events. Outcomes were selected based on previous recommendations established by the FDA for evaluating treatment benefit in clinical trials of IBS.
| Data abstraction
All data were abstracted independently by two investigators (AS and MC) for the primary and secondary outcomes on to a
Microsoft Excel spreadsheet. Authors of included studies were
Key Points
• Studies have indicated a potential benefit of probiotics in IBS, although efficacy of individual strains or specific combinations is unknown.
• While pooled analyses in the current study show no clear benefit with VSL#3 in IBS on abdominal pain or stool consistency, there is a strong trend toward improvement in overall response.
• Further study of VSL#3 in well-defined IBS patients using validated clinical endpoints is required.
contacted for missing data; their provided responses were included in the analyses. 
| Quality of evidence
We used the GRADE approach to evaluate strength of the body of evidence. In this approach, level of evidence is rated as high, moderate, low, or very low based on the following factors: (i) risk of bias,
(ii) indirectness, (iii) unexplained heterogeneity or inconsistency, (iv) imprecision, and (v) probability of publication bias. All factors were considered for each outcome, and were classified as "serious"
or "very serious" if a reason could be found for downgrading the evidence.
| Data synthesis and statistical analysis
We used an intention-to-treat analysis for all dichotomous outcomes with dropouts categorized as non-responders. Continuous outcomes were recorded using all available data. Data were pooled using fixed effects models. Pooled estimates of treatment effect for continuous variables were reported as standardized mean difference (SMD) or mean difference (MD) with 95% confidence intervals (CI). Proportion of overall responders was reported as risk ratio (RR) with 95% CI using the Mantel-Haenszel method. For continuous outcomes, we analyzed the MD in change from baseline. If this variable was not reported and could not be calculated from other data, we used the MD at follow-up. We assessed statistical heterogeneity using the statistic. The statistic represents the proportion of variation across studies that is due to differences between studies beyond chance. >50% indicates significant heterogeneity among studies. 18 Meta-analyses were performed using the "meta" package 19 in R Statistical Software (version 3.4.2) and the significance level set to an alpha of 0.05. When no standard deviation (SD) was reported (Wong et al 10 ) , it was imputed from other studies using the same scale. When a specified endpoint of interest (eg proportion of patients achieving a prespecified endpoint in weekly response for 50% of treatment weeks) was not provided (Staudacher et al 15 ), but data on a similar endpoint were reported, these data were recorded as "surrogate" outcomes and pooled for the meta-analysis. We performed additional prespecified sensitivity analyses to assess the effect of VSL#3 by excluding studies with SD imputation or a surrogate outcome.
| RE SULTS
| Study characteristics
The search strategy used ( 10, 12, 13 One study required an amendment to the protocol after 17 participants completed eight treatment weeks to allow for a 2-week run-in phase followed by a 4-week treatment phase due to difficulties with patient recruitment. 12 One study randomized patients to a co-intervention of sham diet vs low FODMAP diet. 
| Quality of evidence
Quality of evidence is summarized in Table 2 using the GRADE approach as described in the methods. Two studies were considered to be at moderate 10 or high risk of bias 11 due to concerns for selection and reporting bias, and evidence was rated down for outcomes in which these studies were included. Overall, there was high certainty suggesting a lack of benefit on stool consistency and moderate certainty suggesting a trend toward benefit in overall response with VSL#3. For all other outcomes, there was low certainty suggesting lack of benefit of VSL#3.
| Primary outcomes
| Abdominal pain
Four trials 10, 12, 13, 15 appraised pain symptoms based on a 100 mm visual analogue scale. One trial 11 used the Gastrointestinal Symptom Rating Scale (GSRS), a clinical rating scale for IBS. 20 . Overall, no significant difference was observed for mean improvement in ab- Sensitivity analysis excluding one study that required the use of imputed data for the SD of the abdominal pain intensity score 10 showed similar findings (SMD = 0.07; 95% CI −0.21 to 0.34). There was no observed heterogeneity among studies (=0%, P = 0.6).
| Stool consistency
Data for change in percentage of bowel movements with normal stool consistency before and after treatment was available for 177 patients in three studies. 12, 13, 15 There was no significant difference in the change of the proportion of bowel movements with normal consistency (Figure 3 ) for VSL#3 vs placebo (overall MD = 0; 95% CI = −0.09 to 0.08). There was no observed heterogeneity across studies (= 0%, P = 0.71).
| Secondary outcomes
| Overall response
Data for overall response and proportion of stools with normal consistency were available for 177 patients in three studies. 12, 13, 15 Two studies defined a response as achieving a prespecified endpoint (eg satisfactory relief in bloating or IBS symptoms) during at least 50% (Figure 4 ). There was no significant heterogeneity across studies (=0%, P = 0.63).
Sensitivity analysis excluding the trial with overall response defined over the past 7 days demonstrated no significant difference in overall response (RR = 1.18; 95% CI 0.66-2.13) with no significant heterogeneity across studies (=0%, P = 0.48).
| Abdominal bloating
Among the five studies, no significant difference was observed for mean improvement in abdominal bloating ( Figure 5 ) with VSL#3
vs placebo (SMD = 0.15; 95% CI −0.11 to 0.4). There was no significant heterogeneity across studies (=5%, P = 0.38). Sensitivity analysis excluding one trial 10 for which data imputation was required showed similar results (SMD = 0.16; 95% CI −0.12 to 0.44) with no significant heterogeneity across studies (=28%, P = 0.25).
| Quality of life
Data for QOL were available from three studies. 10, 11, 15 No significant differences ( Figure 6 ) between VSL#3 and placebo treated groups were observed for mean improvement in QOL (SMD = −0.08; 95% CI −0.39 to 0.22). There was no significant heterogeneity across studies (=0%, P = 0.65). Sensitivity analysis excluding trial 10 with imputed data showed similar results (SMD = −0.14; 95% CI −0.49 to 0.21) and heterogeneity remained nonsignificant (=0%, P = 0.48).
TA B L E 2 Quality of evidence summarized using the GRADE Approach 
Mean difference
Favors Placebo Favors VSL#3
| Adverse events
Only one study 15 reported adverse events, which included worsened GI symptoms, in 7.8% of placebo patients and 3.8% of VSL#3 patients.
| D ISCUSS I ON
Although individual trials have shown evidence for benefit with Recommendations for evaluating treatment response have focused on "overall response" defined as a prespecified improvement in weekly or daily response for at least 50% of treatment weeks. 
Standardized mean difference
Favors Placebo Favors VSL#3 
Favors Placebo Favors VSL#3
response between treatment groups. This lack of effect is generally consistent with findings reported in individual studies and a prior systematic review of probiotics in IBS, in which subgroup analysis of three trials using VSL#3 in IBS showed no significant benefit compared to placebo on global or abdominal pain scores. 8 At the same time, few adverse events were reported, and VSL#3
appears to be safe and well-tolerated in IBS.
The precise mechanisms by which VSL#3 exerts potentially beneficial effects are unknown. In vivo and in vitro studies have suggested that VSL#3 may modulate host-immune response, intestinal microbiota, anti-inflammatory pathways, visceral pain responses, and epithelial barrier function. 
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